Group 1 - The core point of the news is that 麦澜德 (688273) has seen a net financing increase of 66.9 million yuan on November 10, with a total financing balance of 1.24 billion yuan, indicating a positive trend in investor interest [1][2][3] - In the last three trading days, 麦澜德 has accumulated a net financing buy of 330.68 million yuan, showing consistent demand from investors [1] - Over the past 20 trading days, there have been 11 days with net financing purchases, reflecting a sustained interest in the stock [1] Group 2 - The financing balance on November 10 was 1.24 billion yuan, which is an increase of 0.54% from the previous day [2][3] - The financing net purchases for the previous trading days were 159.72 million yuan on November 7 and 104.06 million yuan on November 6, indicating a growing trend in financing activity [2][3] - The financing balance has shown a steady increase over the past few days, with a notable rise from 1.20 billion yuan on November 4 to 1.24 billion yuan on November 10 [2][3]

Core Insights - Jiangning High-tech Zone has significantly improved its competitiveness ranking, moving up 4 places to 13th in the 2024 National Biopharmaceutical Industry Park Competitiveness Ranking released at the 2025 China Biotechnology Innovation Conference [3][4] - The ranking is based on a comprehensive evaluation of various dimensions including environment, industry, technology, talent, and cooperation, aimed at promoting the development and transformation of China's biopharmaceutical industry clusters [3] Group 1: Industry Overview - Jiangning High-tech Zone is recognized as a key cluster for the biopharmaceutical industry in the Yangtze River Delta, positioning biopharmaceuticals as its primary industry for regional transformation [3] - The park has attracted nearly 400 pharmaceutical companies, covering six major sectors including new drug development, cell and gene therapy, and high-end medical devices [3] Group 2: Performance Metrics - In 2024, the park successfully listed two Class 1 innovative drugs, with the pharmaceutical industry's revenue growth exceeding 30%, leading the city [3] - By the beginning of 2025, Jiangsu Province's first Class 1 innovative drug was developed in this zone, with a nearly 40% revenue growth for the first three quarters of the year, showcasing the industry's explosive growth potential [3][4] Group 3: Strategic Focus Areas - Jiangning High-tech Zone is strategically focusing on four emerging sectors: cell and gene therapy, nuclear medicine, beauty and health, and brain-computer interfaces, employing a model of "leading enterprises + chain extension + ecosystem construction" to build a competitive industrial cluster [4] - In the cell and gene therapy sector, the zone has established a complete industrial chain from gene synthesis to commercial production, leveraging leading companies such as Genscript and Ruigen Biotech [4] - The nuclear medicine sector aims to create a comprehensive ecosystem in collaboration with GE Healthcare and Dongcheng Andico, focusing on the entire production chain from target discovery to clinical transformation [4]

Core Viewpoint - Nanjing Medlander Medical Technology Co., Ltd. will hold a Q3 2025 earnings presentation on November 18, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Earnings Presentation Details - The earnings presentation is scheduled for November 18, 2025, from 9:00 to 10:00 AM [2][4]. - The event will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][4]. - Investors can submit questions from November 11 to November 17, 2025, through the Roadshow Center website or via the company's email [5][6]. Group 2: Company Governance - The presentation will include participation from key executives, including the Chairman, General Manager, and Financial Director [4]. - The company assures that the content of the announcement is accurate and complete, with no misleading statements [1][8]. Group 3: Shareholder Meeting - A temporary shareholder meeting was held on November 7, 2025, with all resolutions passed without any objections [9][10]. - The meeting was conducted in compliance with relevant laws and regulations, ensuring its legality and validity [11][14]. - Key resolutions included profit distribution and changes to the company's registered address [13].

证券代码：688273 证券简称：麦澜德 公告编号：2025-047 南京麦澜德医疗科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 18 日 （星期二） 9:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 11 日 （星期二） 至 11 月 17 日 （星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （mld@medlander.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 南京麦澜德医疗科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 23 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2025 年第 ...

证券代码：688273 证券简称：麦澜德 公告编号：2025-046 南京麦澜德医疗科技股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 11 月 7 日 （二） 股东会召开的地点：南京市雨花台区凤展路 32 号 A2 栋北公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 46 | | --- | --- | | 普通股股东人数 | 46 | | 2、出席会议的股东所持有的表决权数量 | 60,493,804 | | 普通股股东所持有表决权数量 | 60,493,804 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 61.85 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 61.85 | （四） 表决方式 ...

致：南京麦澜德医疗科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》及中国证券监督管理委员会发布的《上市公司股东会规则》等规 定，北京市中伦律师事务所（以下简称"本所"）接受南京麦澜德医疗科技股份 有限公司（以下简称"公司"）的委托，指派本所律师对公司 2025 年第三次临 时股东会（以下简称"本次股东会"）进行见证并就相关事项出具本法律意见书。 北京市中伦律师事务所 关于南京麦澜德医疗科技股份有限公司 本法律意见书仅就本次股东会的召集人资格、召集和召开程序、出席本次股 东会人员的资格、会议表决程序是否符合法律、法规、规范性文件及《公司章程》 的规定以及表决结果是否合法有效发表意见，而不对本次股东会所审议的议案内 容以及该等议案所表述的相关事实或数据的真实性、准确性或合法性发表意见。 2025 年第三次临时股东会的 法律意见书 本法律意见书仅供公司本次股东会之目的使用，未经本所书面同意，不得用 作其他任何目的。 为出具本法律意见书，本所律师列席了本次股东会，并根据有关法律、法规、 规范性文件的规定和要求，按照律师行业公认的业务标准、道德规范和勤勉尽责 1 法律 ...

Core Viewpoint - 麦澜德's stock price has shown significant volatility, with a year-to-date increase of 73.20%, but a recent decline of 4.53% over the past five trading days, indicating potential market fluctuations and investor sentiment changes [1][2]. Company Overview - 南京麦澜德医疗科技股份有限公司, established on January 16, 2013, and listed on August 11, 2022, specializes in the research, production, sales, and services related to pelvic and postpartum rehabilitation products [1]. - The company's revenue composition includes: pelvic rehabilitation products (36.98%), reproductive rehabilitation products (33.10%), consumables and accessories (24.32%), sports rehabilitation products (2.77%), and other products (2.84%) [1]. Financial Performance - For the period from January to September 2025, 麦澜德 reported a revenue of 344 million yuan, reflecting a year-on-year growth of 4.01%, while the net profit attributable to shareholders was approximately 95.6 million yuan, showing a slight decrease of 0.07% [2]. - Since its A-share listing, 麦澜德 has distributed a total of 268 million yuan in dividends [3]. Shareholder and Market Activity - As of September 30, 2025, 麦澜德 had 6,402 shareholders, an increase of 17.23% from the previous period, with an average of 5,752 circulating shares per shareholder, down by 14.70% [2]. - The stock has seen significant trading activity, with a recent net inflow of 686,900 yuan from major funds, indicating ongoing interest from institutional investors [1].

南京麦澜德医疗科技股份有限公司 2025 年第三次临时股东会会议资料 南京麦澜德医疗科技股份有限公司 2025 年第三次临时股东会会议资料 目 录 | 2025 年第三次临时股东会会议须知 | 3 | | --- | --- | | 2025 年第三次临时股东会会议议程 | 5 | | 议案一：关于 2025 年前三季度利润分配方案的议案 | 7 | | 议案二：关于变更公司注册地址、修订《公司章程》并办理工商变更登记的议案8 | | 南京麦澜德医疗科技股份有限公司 2025 年第三次临时股东会会议资料 证券代码：688273 证券简称：麦澜德 南京麦澜德医疗科技股份有限公司 2025 年第三次临时股东会会议资料 2025 年 11 月 南京麦澜德医疗科技股份有限公司 2025 年第三次临时股东会会议须知 为维护全体股东的合法权益，确保南京麦澜德医疗科技股份有限公司（以下 简称"公司"）股东会顺利进行，根据《中华人民共和国证券法》《中华人民共和国 公司法》等法律法规及《南京麦澜德医疗科技股份有限公司章程》和公司《股东 会议事规则》的相关规定，制定以下会议须知，请出席股东会的全体人员严格遵 守。 一、全体参会人 ...

Core Points - The company announced that its third extraordinary general meeting of shareholders in 2025 will review two proposals [1] Group 1: Profit Distribution Plan - For the first three quarters of 2025, the company reported a net profit of 95.9987 million yuan and plans to distribute a cash dividend of 3 yuan (including tax) for every 10 shares to all shareholders [1] - After deducting shares in the repurchase special account, the participating shares for the dividend distribution amount to 97.8079 million shares, with a total cash dividend of 29.3424 million yuan (including tax) proposed [1] - The company will not increase capital through reserve funds or issue bonus shares [1] Group 2: Company Registration Change - The second proposal involves changing the company's registered address and amending the Articles of Association, with the new registered address proposed to be No. 1 Hualin Road, Jiangning District, Nanjing City [1]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return that will outperform the market benchmark by more than 15% over the next 6-12 months [7]. Core Insights - The company reported a stable revenue growth of 4.01% year-on-year for the first three quarters of 2025, achieving a total revenue of 344 million yuan. The net profit attributable to the parent company was approximately 96 million yuan, showing a slight decrease of 0.07% year-on-year. In Q3 2025, the company generated a revenue of 103 million yuan, a year-on-year increase of 0.42%, while the net profit attributable to the parent company rose by 36.71% to 32 million yuan, primarily due to increased financial subsidies [5][6]. - The company is focusing on high-potential business areas such as brain-computer interfaces, with several key projects underway, including a national key research plan and various provincial initiatives aimed at developing advanced rehabilitation technologies [6]. Financial Performance Summary - For the fiscal year 2025, the company is projected to achieve revenues of 500 million yuan, with a year-on-year growth rate of 17.8%. The net profit attributable to the parent company is expected to be 117 million yuan, reflecting a growth of 15.0%. The earnings per share (EPS) for 2025 is estimated at 1.17 yuan, with a price-to-earnings (P/E) ratio of 34x [11][7]. - The financial forecasts for 2026 and 2027 indicate continued growth, with revenues expected to reach 613 million yuan and 748 million yuan, respectively, and net profits of 164 million yuan and 203 million yuan, with corresponding growth rates of 40.7% and 23.7% [11][7].